scholarly journals The prevalence of chronic pancreatitis in patients with the first diagnosed pulmonary tuberculosis

2017 ◽  
Vol 36 (2) ◽  
pp. 49-52
Author(s):  
L. D. Todoriko ◽  
I. O. Semianiv
Keyword(s):  
Drug Resistance ◽  
Chronic Pancreatitis ◽  
Side Effects ◽  
Pulmonary Tuberculosis ◽  
Adverse Reactions ◽  
Biliary System ◽  
Tuberculosis Treatment ◽  
Pancreatic Lesion ◽  
Antituberculous Drugs ◽  
The Future

Despite the reduction in the incidence of tuberculosis, the side effects of antimycobacterial drugs limit the conduction of a complete chemotherapy. They often develop upon comorbid pancreatic lesion. Analysis has shown that chronic pancreatitis is observed in 22.2% of cases. It is found that lesions of the pancreas occur 1.7 times more often in patients with resistant forms of tuberculosis than in patients with more sensitive forms. Lack of proper attention to comorbidity from hepato-pancreatic-biliary system leads to the development of adverse reactions to tuberculosis treatment, which in the future may lead to a temporary cancellation of antituberculous drugs, development of drug resistance and ineffective treatment.  

scholarly journals Case Series of Three Patients with Rifampicin-Induced Thrombocytopenia

2020 ◽  
Author(s):  
Chandramouli M.T
Keyword(s):  
Pulmonary Tuberculosis ◽  
Adverse Reactions ◽  
Rare Complication ◽  
Case Series ◽  
Tuberculosis Treatment ◽  
Effective Drug ◽  
Antitubercular Drugs ◽  
Short Course ◽  
Life Threatening

AbstractLife-threatening adverse reactions of antitubercular drugs are uncommon; however, thrombocytopenia is one such rare complication encountered with rifampicin, isoniazid, ethambutol, and pyrazinamide. Rifampicin is the most effective drug and its use in the tuberculosis treatment led to the emergence of modern and effective short-course regimens. I am reporting case series of three patients with pulmonary tuberculosis presented with rifampicin-induced thrombocytopenia.

scholarly journals The Effect of Side Effects Tuberculosis Treatment in the Early Stage Towards Compliance with Tuberculosis Patients

2021 ◽  
Vol 5 (01) ◽  
pp. 29-32
Author(s):  
Joko Sapto Pramono ◽  
Nilam Noorma ◽  
Andi Lis Arming Gandini ◽  
Sopia Fitriani
Keyword(s):  
Side Effects ◽  
Pulmonary Tuberculosis ◽  
Health Workers ◽  
Early Stage ◽  
Treatment Compliance ◽  
Tuberculosis Treatment ◽  
Cross Sectional ◽  
Tuberculosis Patients ◽  
Early Stages ◽  
Significant Difference

Pulmonary tuberculosis treatment causes various side effects including nausea and vomiting, itching, vision problems, and anemia. Drug side effects in the early stages are one of the causes of non-adherence to complete treatment. The purpose of this study was to analyze the effect of the side effects Tuberculosis treatment in the early stages on treatment compliance for tuberculosis patients. This study used a cross sectional design. Samples were taken as many as 71 respondents, the instruments used were side effects of early-stage tuberculosis treatment and compliance with tuberculosis treatment in tuberculosis patients from the Morisky Medication Adherence Scale (MMAS). The results of the study found 97.7% adherent and 2.3% non-adherent, 39.5% mild side effects and 60.5% severe side effects. Chi-square test showed that no significant difference between the side effects of TB treatment in the early stages of tuberculosis treatment compliance in patients p = 0.669 at significant level of 95% (α = 0.05). There was no effect between the side effects of Tuberculosis treatment in the early stages of treatment compliance for Tuberculosis patients. It was recommended that health workers continue to monitor the side effects of tuberculosis treatment and provide motivation to carry out treatment completely. Keywords: side effects; early stage; treatment; pulmonary tuberculosis; compliance

Clinical tolerance of single doses of ethionamide in patients with pulmonary tuberculosis

1982 ◽  
Vol 63 (4) ◽  
pp. 61-63
Author(s):  
G. A. Smirnov ◽  
L. T. Zamaletdinova ◽  
V. A. Mikhailovskaya ◽  
S. I. Latypova
Keyword(s):  
Single Dose ◽  
Gastrointestinal Tract ◽  
Side Effects ◽  
Pulmonary Tuberculosis ◽  
Chronic Diseases ◽  
Adverse Reactions ◽  
Number Of Patients

The tolerance of ethionamide was studied in 851 patients with pulmonary tuberculosis. The drug was administered at 0.75 g at a time. Side effects were noted in 31% of individuals, and complete intolerance - in 6.6%. For the rest, adverse reactions disappeared after a short break in taking the drug or when it was administered at night. In a number of patients, to remove side effects, it was necessary to reduce a single dose of ethionamide to 0.5 g or give it 0.25 g three times. More often, side complications occurred in persons with chronic diseases of the gastrointestinal tract, as well as in elderly and senile patients.

scholarly journals Adverse reactions to anti-tuberculous drugs in patients with pulmonary tuberculosis and ways to eliminate them

2020 ◽  
pp. 13-16
Author(s):  
M.M. Kuzhko ◽  
V.M. Melnyk ◽  
М.І. Gumeniuk ◽  
T.V. Tlustova ◽  
T.A. Sprynsian
Keyword(s):  
Side Effects ◽  
Pulmonary Tuberculosis ◽  
Retrospective Analysis ◽  
Medical Records ◽  
Adverse Reactions ◽  
Treatment Effectiveness ◽  
Medical Sciences ◽  
Impact On Treatment ◽  
Practical Recommendations

ABSTRACT. Here we present the results of retrospective analysis of medical records of 2292 patients with all forms of pulmonary tuberculosis aged 20 to 65 years, who were treated at the National Institute of Tuberculosis and Pulmonology named after F.G. Yanovsky of National Academy of Medical Sciences of Ukraine in 2000-2018. We analyzed the most common side effects of anti-tuberculous drugs and their impact on treatment effectiveness. Practical recommendations for the elimination of adverse reactions to anti-tuberculous drugs in order to increase the effectiveness of treatment of patients with pulmonary tuberculosis are given here.

Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy

2020 ◽  
Vol 27 (13) ◽  
pp. 2118-2132 ◽  
Author(s):  
Aysegul Hanikoglu ◽  
Hakan Ozben ◽  
Ferhat Hanikoglu ◽  
Tomris Ozben
Keyword(s):  
Oxidative Stress ◽  
Drug Resistance ◽  
Side Effects ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Anticancer Drugs ◽  
Chemotherapeutic Agents ◽  
Oxidation Reactions ◽  
Hybrid Compounds ◽  
Induced Apoptosis

: Elevated Reactive Oxygen Species (ROS) generated by the conventional cancer therapies and the endogenous production of ROS have been observed in various types of cancers. In contrast to the harmful effects of oxidative stress in different pathologies other than cancer, ROS can speed anti-tumorigenic signaling and cause apoptosis of tumor cells via oxidative stress as demonstrated in several studies. The primary actions of antioxidants in cells are to provide a redox balance between reduction-oxidation reactions. Antioxidants in tumor cells can scavenge excess ROS, causing resistance to ROS induced apoptosis. Various chemotherapeutic drugs, in their clinical use, have evoked drug resistance and serious side effects. Consequently, drugs having single-targets are not able to provide an effective cancer therapy. Recently, developed hybrid anticancer drugs promise great therapeutic advantages due to their capacity to overcome the limitations encountered with conventional chemotherapeutic agents. Hybrid compounds have advantages in comparison to the single cancer drugs which have usually low solubility, adverse side effects, and drug resistance. This review addresses two important treatments strategies in cancer therapy: oxidative stress induced apoptosis and hybrid anticancer drugs.

Recent Advances in the Rational Drug Design Based on Multi-target Ligands

2020 ◽  
Vol 27 (28) ◽  
pp. 4720-4740 ◽  
Author(s):  
Ting Yang ◽  
Xin Sui ◽  
Bing Yu ◽  
Youqing Shen ◽  
Hailin Cong
Keyword(s):  
Drug Resistance ◽  
Clinical Practice ◽  
Side Effects ◽  
Drug Design ◽  
Rational Drug Design ◽  
Health Conditions ◽  
Pharmacokinetic Parameters ◽  
Single Target ◽  
Rational Drug ◽  
Huge Challenge

Multi-target drugs have gained considerable attention in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance. Single-target drugs, although highly selective, may not necessarily have better efficacy or fewer side effects. Therefore, more attention is being paid to developing drugs that work on multiple targets at the same time, but developing such drugs is a huge challenge for medicinal chemists. Each target must have sufficient activity and have sufficiently characterized pharmacokinetic parameters. Multi-target drugs, which have long been known and effectively used in clinical practice, are briefly discussed in the present article. In addition, in this review, we will discuss the possible applications of multi-target ligands to guide the repositioning of prospective drugs.

Sign in / Sign up

Export Citation Format

Share Document